MBX Biosciences Statistics

Total Valuation

MBX Biosciences has a market cap or net worth of $359.31 million. The enterprise value is $118.66 million.

Market Cap	359.31M
Enterprise Value	118.66M

Important Dates

The next estimated earnings date is Saturday, August 16, 2025, before market open.

Earnings Date	Aug 16, 2025
Ex-Dividend Date	n/a

Share Statistics

MBX Biosciences has 33.42 million shares outstanding. The number of shares has increased by 1,591.64% in one year.

Current Share Class	33.42M
Shares Outstanding	33.42M
Shares Change (YoY)	+1,591.64%
Shares Change (QoQ)	+0.06%
Owned by Insiders (%)	3.16%
Owned by Institutions (%)	50.83%
Float	13.61M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.46
P/TBV Ratio	1.53
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 23.31, with a Debt / Equity ratio of 0.00.

Current Ratio	23.31
Quick Ratio	23.11
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -48.22% and return on invested capital (ROIC) is -33.35%.

Return on Equity (ROE)	-48.22%
Return on Assets (ROA)	-31.68%
Return on Invested Capital (ROIC)	-33.35%
Return on Capital Employed (ROCE)	-34.58%
Revenue Per Employee	n/a
Profits Per Employee	-$1.71M
Employee Count	43
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	10.95
200-Day Moving Average	n/a
Relative Strength Index (RSI)	47.60
Average Volume (20 Days)	324,287

Short Selling Information

The latest short interest is 4.65 million, so 13.92% of the outstanding shares have been sold short.

Short Interest	4.65M
Short Previous Month	4.75M
Short % of Shares Out	13.92%
Short % of Float	34.19%
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-81.41M
Pretax Income	-47.20M
Net Income	-73.47M
EBITDA	-81.14M
EBIT	-81.41M
Earnings Per Share (EPS)	-$3.93

Full Income Statement

Balance Sheet

The company has $240.79 million in cash and $130,000 in debt, giving a net cash position of $240.66 million or $7.20 per share.

Cash & Cash Equivalents	240.79M
Total Debt	130,000
Net Cash	240.66M
Net Cash Per Share	$7.20
Equity (Book Value)	235.42M
Book Value Per Share	7.04
Working Capital	233.80M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$66.65 million and capital expenditures -$631,000, giving a free cash flow of -$67.28 million.

Operating Cash Flow	-66.65M
Capital Expenditures	-631,000
Free Cash Flow	-67.28M
FCF Per Share	-$2.01

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

MBX Biosciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,591.64%
Shareholder Yield	-1,591.64%
Earnings Yield	-20.45%
FCF Yield	-18.72%

Analyst Forecast

The average price target for MBX Biosciences is $37.40, which is 247.91% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$37.40
Price Target Difference	247.91%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2